Market Overview

UPDATE: Aegis Capital Initiated Ironwood Pharmaceuticals with Buy, $17 PT; Unique Gastrointestinal Opportunity

Share:
Related IRWD
Empire Analyst: Sell Sucampo Pharma, It Has 50% Downside
Benzinga's Top Initiations

In a recently released report, Aegis Capital said it initiated coverage on Ironwood Pharmaceuticals (NASDAQ: IRWD) with a Buy rating and a $17 price target on shares.

Aegis Capital commented, "The current market for chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C) is substantial, with over 100mm people estimated to suffer from these disorders in the U.S., Europe, and Japan. Roughly 8mm individuals in the U.S. alone seek treatment for constipation-related disorders every year. Existing therapies are either only palliative or marginally effective, with substantial side effect risk. We believe this creates a compelling opportunity for firms like Ironwood, since linaclotide is based on a naturally-occurring hormone called uroguanylin and utilizes an evolutionarily-derived mechanism of action."

Ironwood Pharmaceuticals closed at $13.87 on Friday.

Latest Ratings for IRWD

DateFirmActionFromTo
Jan 2016Mizuho SecuritiesInitiates Coverage onBuy
Dec 2015BTIG ResearchInitiates Coverage onBuy
May 2015Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for IRWD
View the Latest Analyst Ratings

Posted-In: Aegis CapitalAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (IRWD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters